Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin vs Glimepiride in Type 2 Diabetes
NCT07365358Phase 4Not yet recruiting
- Sponsor
- Chong Kun Dang Holdings
- Start
- Mar 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Chong Kun Dang Holdings. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07365358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07365358.